European Market Size Analysis for Medical Devices
Market size and comparative landscape using reliable hospital statistics
White Paper: Evidence Requirements for the Creation of IVD Reimbursement (NABM) Codes in France
Get insights from MTRC White Papers to advance your understanding on HAS assessments and evidence generation strategy for IVD tests in France
Recent news and posts
Update to the List of Innovative Procedures Outside the Nomenclature in France
In April 2026, the French Ministry of Health, Family, Autonomy, and People with Disabilities updated the List of Innovative Procedures Outside the Nomenclature (LAHN). The list forms part of the Repository of Innovative Procedures Outside the Nomenclature of Biology and Anatomopathology (RIHN), which provides temporary funding for innovative IVD tests until sufficient evidence is available for regular reimbursement (i.e., inclusion in the Nomenclature of Medical Laboratory Procedures, NABM, or the Common Classification of Medical Procedures, CCAM).
LAHN was introduced in 2024 as part of the RIHN reform. Coverage in LAHN is limited to nine years, with a progressive tariff reduction starting January 1, 2025 (a 20% reduction in 2025, followed by an additional 10% reduction each year from 2026 onward). The French National Authority for Health (HAS) evaluates tests on LAHN to determine their eligibility for inclusion in the NABM or CCAM. For tests that receive a positive HAS assessment, the tariff reduction does not apply; these tests are identified by codes beginning with the letter “V.”
The April 2026 update introduced two new duplicative codes in Chapter 02 “Cytogenetics,” both exempt from tariff reductions:
- V016 “DNA microarray hybridization (without verifications)” in the oncology context;
- V017 “Reinterpretation of a DNA Microarray" in the oncology context.
These new codes complement the existing B-codes with the same descriptions used in the prenatal setting, which remain subject to the tariff reduction mechanism.
This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.